Nanomerics uses its world-leading pharmaceutical nanotechnology to develop new medicines faster, cheaper, and with dramatically reduced risk. Nanomerics proprietary technology boosts the activity of hydrophobic drugs and peptides by getting them where they need to be. This allows the creation of new medicines based on known drug compounds that now can be given in new ways and for new indications. Nanomerics’ Molecular Envelope Technology (MET) is applicable to a broad range of compounds and allows targeting of diseases via the oral and nasal route, delivery to the eye, and across the blood-brain-barrier. Nanomerics offers its medicines development capability and expertise to partners wanting to enable specific drugs, e.g. the company is currently working with a NSADAQ company on two oral products and an Asian company on nasal delivery. Nanomerics also develops its own nano-enabled medicines and has products targeting the ophthalmic market as well as oral medicines e.g. in the area of oncology. Its lead product is a peptide for the treatment of chronic pain. The endogenous peptide is already known to be efficacious and safe. Combination with the MET system creates a nano-enabled medicine that avoids some of the significant problems of current opioid drugs.